文献速递肝病

非酒精性脂肪性肝病与代谢相关脂肪性肝病之间是否存在结局差异?

Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
PubMed 文献 · Hepatology · 2022-05-02

研究基于NHANES III和NHANES 2017-2018数据,比较非酒精性脂肪性肝病(NAFLD)与代谢相关脂肪性肝病(MAFLD)的长期结局。结果显示两者临床特征和长期结局相似,诊断一致性高(kappa系数0.83-0.94),NAFLD肝病死亡由胰岛素抵抗驱动,MAFLD死亡主要由酒精相关性肝病驱动。

要点

  • MAFLD与NAFLD诊断一致性高,kappa系数为0.83-0.94。
  • 两组全因死亡和病因特异性死亡累积死亡率无差异。
  • NAFLD肝病死亡预测因素为胰岛素抵抗,MAFLD死亡预测因素为酒精相关性肝病。

核心结论

  • MAFLD与NAFLD具有相似的临床特征和长期结局。
  • NAFLD中肝病死亡增加由胰岛素抵抗驱动,MAFLD中主要由酒精相关性肝病驱动。

研究设计与样本

  • 研究纳入NHANES III和NHANES 2017-2018中脂肪性肝病患者,NHANES III用超声定义中重度肝脂肪变,NHANES 2017-2018用受控衰减参数≥285 dB/m定义。
  • NAFLD定义为FLD且无其他肝病和过量饮酒,MAFLD定义为FLD且符合代谢功能障碍标准。
  • NHANES III参与者(n=12,878)有截至2015年12月31日的死亡数据;NHANES 2017-2018参与者(n=4,328)。

主要发现

  • NHANES III参与者平均年龄43.1岁,49.5%男性,FLD占20.3%,NAFLD占16.5%,MAFLD占18.1%。
  • NHANES 2017-2018参与者平均年龄48.0岁,49.1%男性,FLD占36.8%,NAFLD占34.2%,MAFLD占36.3%。
  • 两个数据集中MAFLD与NAFLD诊断一致性高,kappa系数=0.83-0.94。
  • 除定义组成部分(如MAFLD的饮酒)外,临床特征无其他主要差异。
  • 随访长达27年(中位22.8年),全因死亡和病因特异性死亡累积死亡率无差异。

关键数值与推荐

  • NHANES III中FLD定义为超声显示中重度肝脂肪变,NHANES 2017-2018中定义为受控衰减参数≥285 dB/m。
  • NAFLD定义为FLD且无其他肝病和过量饮酒,MAFLD定义为FLD且符合代谢功能障碍标准。
  • MAFLD与NAFLD诊断一致性kappa系数=0.83-0.94。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the association of NAFLD with metabolic risks, a name change to MAFLD is proposed. We compared the long-term outcomes of NAFLD and MAFLD. METHODS: We included patients with fatty liver disease (FLD) from NHANES III and NHANES 2017-2018 (FLD defined as moderate to severe hepatic steatosis by ultrasound for NHANES III and as having a controlled attenuation parameter ≥285 dB/m for NHANES 2017-2018). NAFLD was defined as FLD without other liver diseases and excess alcohol use. Metabolic-associated fatty liver disease (MAFLD) was defined as FLD and metabolic dysfunction per criteria. All NHANES III participants had linked mortality data through December 31, 2015. RESULTS: NHANES III participants (n = 12,878): mean age 43.1 years old; 49.5% male; 20.3% with FLD, 16.5% with NAFLD, and 18.1% with MAFLD. NHANES 2017-2018 participants (n = 4328): mean age 48.0 years old; 49.1% male; 36.8% with FLD, 34.2% with NAFLD, and 36.3% with MAFLD. Excellent concordance was noted between MAFLD and NAFLD diagnosis in both data sets (kappa coefficient = 0.83-0.94). Except for components of each definition (e.g., alcohol use for MAFLD), no other major differences in clinical characteristics were noted. During up to 27 years of follow-up (median of 22.8 years), no differences in cumulative all-cause and cause-specific mortality were noted. In addition to the stage of fibrosis, insulin resistance was a predictor of liver mortality in NAFLD, and alcohol-associated liver disease (ALD) was a predictor of mortality in MAFLD. CONCLUSIONS: MAFLD and NAFLD have similar clinical profiles and long-term outcomes. The increased liver-related mortality among NAFLD is driven by insulin resistance, and among MAFLD is primarily driven by ALD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Paik JM, Al Shabeeb R, et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology. 2022. PMID: 35363908. doi:10.1002/hep.32499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。